{
  "id": 12915916,
  "title": "Large-scale cerebrospinal fluid proteomics identifies diagnostic biomarker candidates across the clinico-pathological continuum of frontotemporal lobar degeneration",
  "url": "https://urgent.news/2026/10/08/large-scale-cerebrospinal-fluid-proteomics-identifies-diagnostic",
  "topic": "science",
  "section": "Science",
  "published": "2026-10-08T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.29.755483v1?rss=1"
  },
  "original_language": "en",
  "account": "Frontotemporal lobar degeneration (FTLD), primarily driven by tau and TDP-43 proteinopathies, is a frequent cause of early-onset dementia. Currently, there are no reliable biomarkers for distinguishing FTLD subtypes, which complicates in-vivo diagnosis and clinical trial stratification. To address this, researchers carried out large-scale, multi-platform cerebrospinal fluid (CSF) proteomics on 566 individuals, comprising 274 FTLD-spectrum cases (48 with autopsy-confirmed FTLD-TDP, 90 with autopsy-confirmed FTLD-tau), 171 Alzheimer's disease patients, and 95 controls.\n\nThe study identified matrix metalloproteinase MMP10 as a potential diagnostic biomarker for Pick's disease (PiD) versus other FTLD subtypes, achieving near-perfect accuracy across different proteomic platforms. To further validate MMP10, the researchers developed a targeted immunoassay in an independent cohort of autopsy-confirmed FTLD patients. Additionally, the study discovered that post-synaptic proteins HOMER1 and DLG4 were elevated in FTLD-TDP subtypes (A, B, and C) compared to FTLD-tau. Network analysis revealed distinct proteomic signatures in FTLD-TDP, including RNA metabolism and pro-inflammatory pathways, as well as cytoskeletal and heat shock pathways in progressive supranuclear palsy. These findings unveil candidate diagnostic biomarkers and shed light on the intricate proteomic pathways underlying FTLD's complex clinical and pathological diversity.",
  "summary": "Frontotemporal lobar degeneration (FTLD), predominantly comprised of tau and TDP-43 proteinopathies, is a common cause of early-onset dementia. Biomarkers that reliably classify FTLD subtypes are limited, thereby hindering in-vivo diagnosis and clinical trial stratification. We conducted large-scale, multi-platform cerebrospinal fluid proteomics in 566 individuals, including 274 FTLD-spectrum (48…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}